Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Luseogliflozin SCHEMBL16155082 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Luseogliflozin SCHEMBL18265378 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Luseogliflozin SCHEMBL1487519 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Luseogliflozin SCHEMBL27177461 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Luseogliflozin SCHEMBL900678 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Luseogliflozin SCHEMBL18629765 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Luseogliflozin SCHEMBL16153589 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Luseogliflozin SCHEMBL17278233 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| SCHEMBL903229 | 0.93 | SLC5A2 (0.87) | SLC5A2SLC5A1 | |
| SCHEMBL17189390 | 0.93 | SLC5A2 (0.87) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1348 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746887-A1 | METHODS OF TREATING CHRONIC KIDNEY DISEASE (CKD) OR CKD AND HYPERTENSION WITH LORUNDROSTAT, OR A COMBINATION OF LORUNDROSTAT AND A SGLT2 INHIBITOR | Mineralys Therapeutics, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4369158-B1 | TOUCH DISPLAY DEVICE | LG DISPLAY CO LTD (KR) | 2026-05-20 | — | — | EP | claimed |
| EP-4727528-A1 | A PHARMACEUTICAL FORMULATION COMPRISING LINAGLIPTIN, METFORMIN AND A SGLT-2 INHIBITOR | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi (TR) | 2026-04-22 | — | — | EP | claimed |
| EP-4729635-A2 | DIAGNOSIS AND TREATMENT OF NAFLD AND LIVER FIBROSIS | Beth Israel Deaconess Medical Center, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4719430-A1 | COMBINATION TREATMENT AND/OR PREVENTION OF RENAL DISEASES AND/OR HYPERTENSION IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND TELMISARTAN | Boehringer Ingelheim Vetmedica GmbH (DE) | 2026-04-08 | — | — | EP | claimed |
| US-20260069550-A1 | TRANSDERMAL DELIVERY OF ANTIDIABETIC AGENTS | RITTENHOUSE CHRISTINE (US) | 2026-03-12 | — | — | US | claimed |
| EP-4701626-A1 | AMORPHOUS OBICETRAPIB AND SGLT2 INHIBITOR COMBINATION | NewAmsterdam Pharma B.V. (NL) | 2026-03-04 | — | — | EP | claimed |
| CN-121575079-A | SGLT1/2 double-target inhibitor, screening method and application thereof, and diabetes treatment drug | 广东药科大学 | 2026-02-27 | — | — | CN | claimed |
| US-12551484-B2 | Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor | RESVERLOGIX CORP. (CA) | 2026-02-17 | — | — | US | claimed |
| EP-4691459-A1 | COMBINATION FORMULATION COMPRISING SACUBITRIL-VALSARTAN AND SGLT-2 INHIBITOR HAVING IMPROVED STABILITY AND DISSOLUTION RATE | Hanmi Pharm. Co., Ltd. (KR) | 2026-02-11 | — | — | EP | claimed |
| US-20220088144-A1 | SGLT-2 INHIBITORS OR IL-1R ANTAGONISTS FOR REDUCTION OF HYPOGLYCAEMIA AFTER BARIATRIC SURGERY | UNIVERSITÄTSSPITAL BASEL (CH) | 2022-03-24 | — | — | US | claimed |
| WO-2022051316-A1 | FIXED DOSE COMBINATIONS OF CHS-131 AND A SGLT-2 INHIBITOR | Coherus Biosciences, Inc. (US) | 2022-03-10 | — | — | WO | claimed |
| WO-2022051323-A1 | FIXED DOSE COMBINATIONS OF CHS-131 AND A PPAR AGONIST | Coherus Biosciences, Inc. (US) | 2022-03-10 | — | — | WO | claimed |
| WO-2022051319-A1 | FIXED DOSE COMBINATIONS OF CHS-131 AND A DPP-4 INHIBITOR | Coherus Biosciences, Inc. (US) | 2022-03-10 | — | — | WO | claimed |
| WO-2022051318-A1 | FIXED DOSE COMBINATIONS OF CHS-131 AND A THYROID RECEPTOR BETA AGONIST | Coherus Biosciences, Inc. (US) | 2022-03-10 | — | — | WO | claimed |
| WO-2022044014-A1 | COMBINATION THERAPY FOR REDUCING DRUG-INDUCED NEPHROTOXICITY, DYSLIPIDEMIA AND HYPERGLYCEMIA | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2022-03-03 | — | — | WO | claimed |
| WO-2022036506-A1 | COMPOSITION AND USE OF SGLT-2 INHIBITOR AND ANGIOTENSIN RECEPTOR BLOCKERS | 天津睿创康泰生物技术有限公司 | 2022-02-24 | — | — | WO | claimed |
| US-20220054459-A1 | PROPHYLACTIC AND THERAPEUTIC DRUG FOR NONALCOHOLIC FATTY LIVER DISEASE | KOWA COMPANY, LTD (JP) | 2022-02-24 | — | — | US | claimed |
| WO-2022029334-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | GBIOTECH S.À.R.L. (CH) | 2022-02-10 | — | — | WO | claimed |
| WO-2022022865-A1 | METHODS OF TREATING CHRONIC KIDNEY DISEASE WITH DAPAGLIFLOZIN | ASTRAZENECA AB (SE) | 2022-02-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551484-B2 | Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor | SLC5A2, SLC5A1, BRD4 | SLC5A2 1/4885SLC5A1 2/4885 |
| US-20260069550-A1 | TRANSDERMAL DELIVERY OF ANTIDIABETIC AGENTS | SLC5A2, GLP1R, SLC5A1 | SLC5A2 1/4885SLC5A1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.